
Ipsen names new Head of Global Medical Affairs
pharmafile | February 8, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | appointment, ipsen
French pharmaceutical firm Ipsen has announced its recruitment of Dr Sotirios Stergiopoulos as its Senior Vice President and Head of Global Medical Affairs. Stergiopoulos joins the company from Baxalta, a subsidiary of Shire, where he served as Vice President, Head of Global Medical Affairs Oncology.
The appointment was revealed simultaneously with the news that Harout Semerjian has joined Ipsen as its President, Head of Speciality Care International Region and Global Finances.
Throughout his career, Stergiopoulos has held senior medical director positions at Celgene, Novartis and Bayer, preparing him well for his new role with Ipsen. Stergiopoulos will report to Dr Alexandre LeBeaut, current interim head of Ipsen R&D.
LaBeaut commented: “Sotirios brings extensive experience in directing global medical affairs strategies along with a solid expertise in oncology drug development that includes immunology drugs and targeted agents across different tumour indications. Sotirios will play an important role within the R&D leadership team, particularly as we continue to strengthen Ipsen’s oncology portfolio.”
Related Content

Ipsen’s Iqirvo approved for use in NHS Scotland to treat rare liver disease
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental …






